NRGene Technologies Ltd. Logo

NRGene Technologies Ltd.

NRGN | TA

Overview

Corporate Details

ISIN(s):
IL0011720716
LEI:
Country:
Israel
Address:
5 Golda Meir Street, 7403649 Ness Ziona
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

NRGene Technologies Ltd. is a genomics company operating in the agricultural technology (AgTech) sector. It develops and commercializes artificial intelligence (AI)-based software solutions to optimize and accelerate natural breeding programs for plants and animals. By analyzing large genomic datasets with proprietary algorithms, the company's turn-key platforms enable breeding companies and researchers to enhance traits, improve productivity, and increase yields. NRGene's technology supports the development of novel, IP-intensive traits for the global agriculture and food industries, aiming to contribute to a more sustainable future.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for NRGene Technologies Ltd.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-08-09 20:13
Regulatory News Service
Following the completion of its contracted two-year engagement under the Tel Av…
Hebrew (modern) 174.5 KB
2023-08-09 20:13
Business and Financial Review
Following the completion of its contracted two-year engagement under the Tel Av…
Russian 46.0 KB
2023-05-22 23:48
Management Discussion and Analysis
Analysis update report, target price remains 19.8 NIS
English 969.2 KB
2023-05-22 23:48
Earnings Release
Analysis update report, target price remains 19.8 NIS
Russian 70.9 KB
2023-04-13 20:31
Earnings Release
Analysis update - target price t is updated to NIS 19.8
English 959.3 KB
2023-04-13 20:31
Regulatory News Service
Analysis update - target price t is updated to NIS 19.8
Russian 67.3 KB
2022-12-11 20:51
Business and Financial Review
Analysis update report, target price remains 30.9NIS
English 1.1 MB
2022-12-11 20:51
Report Publication Announcement
Analysis update report, target price remains 30.9NIS
Russian 64.0 KB
2022-09-13 22:01
Investor Presentation
update Analysis (FROST) following financial report, target price remains NIS 30…
English 1.2 MB
2022-09-13 22:01
Report Publication Announcement
update Analysis (FROST) following financial report, target price remains NIS 30…
Russian 60.5 KB
2022-08-15 21:22
Investor Presentation
Investors Presentation - August 2022
English 2.5 MB
2022-08-15 21:22
Report Publication Announcement
Investors Presentation - August 2022
Russian 41.9 KB
2022-05-31 21:47
Investor Presentation
Analysis update report, target price remains 30.9NIS
English 1.1 MB
2022-05-31 21:47
Report Publication Announcement
Analysis update report, target price remains 30.9NIS
Russian 55.2 KB
2022-04-03 22:30
Regulatory News Service
Quarterly analysis update report, target price remains 30.9NIS
English 1.1 MB

Automate Your Workflow. Get a real-time feed of all NRGene Technologies Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NRGene Technologies Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN